
Kathera Bioscience: Innovating broad-spectrum drugs to combat global fungal infections.
Kathera Bioscience was founded with the mission to combat the rising global threat of fungal infections through innovative drug development. The company focuses on creating novel, broad-spectrum antifungal therapies that address the limitations of current treatment options. Their core vision is to significantly reduce the global burden of life-threatening fungal diseases by providing more effective and accessible treatment solutions.
Notable figures affiliated with Kathera Bioscience include leading experts in mycology and pharmaceutical development. The company has garnered attention and support from prominent investors in the biotech sector. Key achievements include the development of promising drug candidates that have shown efficacy in preclinical trials. Kathera Bioscience's impact lies in its potential to revolutionize the treatment landscape for fungal infections, offering hope to millions affected globally.

Kainomyx
kainomyx.com

Curie.Bio
curie.bio

Mycologics
mycologics.net

Kymera Therapeutics
kymeratx.com

Zymeron
zymeron.com

Kinnear Pharmaceuticals
kinnearpharma.com

Petri Bio
petribio.com

KBP Biosciences
kbpbiosciences.com

Spectrum Antimicrobials

Aureka Biotechnologies
aurekabio.com

MiniVax

MycoMed Technologies

Nano Cures
nanocures.com

Know Bio
knowbiollc.com

Actio Biosciences
actiobio.com
Companies similar to Kathera Bioscience include Kainomyx, Curie.Bio, Mycologics and Kymera Therapeutics.
Kathera Bioscience was founded in 2020.
Kathera Bioscience's headquarters is located in Union, NJ, US.
Kathera Bioscience's most recent funding round was for $150k (USD) in August 2022.
As of Aug 2, 2022, Kathera Bioscience has raised a total of $150k (USD).
Kathera Bioscience has 3 employees as of Feb 4, 2024.